by MM360 Staff | Jun 13, 2022 | Publications
Oncoimmunology. 2022 May 31;11(1):2081415. doi: 10.1080/2162402X.2022.2081415. eCollection 2022. ABSTRACT Natural Killer (NK) cells are known for their high intrinsic cytotoxic capacity, and the possibility to be applied as ‘off-the-shelf’ product makes...
by MM360 Staff | Jul 7, 2021 | Featured News
Here are the top journal articles from the week of June 24, 2021 as selected by the MYELOMA360 staff. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness...
by MM360 Staff | Jun 23, 2021 | Uncategorized
Source: Cure Today articles Results from a recent study strongly support a treatment regimen of Darzalex with Revlimid and dexamethasone as a new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma. Read More
by MM360 Staff | Jun 23, 2021 | Uncategorized
Source: ASCO Daily News Dr. Mitul Gandhi, a medical oncologist specializing in hematologic malignancies at Virginia Cancer Specialists, which is part of the US Oncology Network, highlights key abstracts from the #ASCO20 Virtual Scientific Program that aim to improve...
by MM360 Staff | Jun 23, 2021 | Myeloma News
Thought provoking findings by #TheRyanGroup in preprint today showing T cell suppression in the tumour microenvironment via stromal cell sialylation is one of the most discussed/tweeted journal articles in Multiple Myeloma this week. Very happy to have been...
